Butcher Arthur C 4

What Happened
Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific (BSX), received shares when performance- and time-based awards vested/converted in mid-February 2026. A total of 58,716 shares were issued to him (50,760 from awards + 7,956 from derivative conversions). To cover tax withholding obligations, 27,914 shares were surrendered/withheld at $74.73 per share, generating proceeds of approximately $2,086,014. Net shares issued to him after withholdings were 30,802.

Key Details

• Transaction dates: conversions/awards dated Feb 13–16, 2026; Form 4 filed Feb 18, 2026.
• Awards/grants: two award entries of 25,380 shares each (performance share programs) and three derivative conversions of 2,237 / 3,173 / 2,546 shares. (Total issued = 58,716.)
• Tax withholding (share surrender): 25,150 + 1,535 + 1,229 = 27,914 shares withheld at $74.73/share for total cash value ~$2,086,014. (Transaction code F = payment of tax liability.)
• Net new shares retained by Butcher after withholding: 30,802.
• Notable footnotes: awards trace to Feb 14, 2023 performance-share grants (F1, F2) that vested based on three-year performance through Dec 31, 2025; RSU = one share per unit (F3); some awards are payable in installments per the footnotes (F5–F7).
• Filing: Form 4 filed Feb 18, 2026 reporting the Feb 13–16 activity (the filing date is shown on the form).

Context

• This was primarily award vesting/conversion and related tax withholding — not an open-market purchase or discretionary sale. In filings, conversion/exercise lines (code M) reflect derivative awards converting to common stock, and withholding (code F) reflects shares surrendered to satisfy tax obligations (a common, routine practice).
• Such automatic withholding/surrender of shares for taxes is standard and does not, by itself, indicate a bullish or bearish signal.
• No post-transaction total holdings were specified in the filing; consult the full Form 4 for complete holding balances and any additional footnote detail.